Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.76 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.66 |
| ▸ | PDE5A | O76074 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908542 | 0.87 | ABCG2 (0.69) | TGFBR1MAPK14ABCG2PDE5ATP53 | |
| SCHEMBL6684058 | 0.86 | TGFBR1 (1.00) | TGFBR1MAPK14PDE5APOLBLMNA | |
| SCHEMBL2911632 | 0.85 | GAA (0.66) | TGFBR1MAPK14ABCG2PDE5ATP53 | |
| SCHEMBL2908573 | 0.85 | ABCG2 (0.66) | TGFBR1MAPK14ABCG2PDE5ATP53 | |
| SCHEMBL2905516 | 0.85 | ABCG2 (0.66) | TGFBR1MAPK14ABCG2PDE5ATP53 | |
| SCHEMBL2911466 | 0.84 | ABCG2 (0.62) | TGFBR1MAPK14ABCG2PDE5ATP53 | |
| SCHEMBL2908491 | 0.82 | PDE5A (0.68) | TGFBR1MAPK14PDE5AMAPTLMNA | |
| SCHEMBL4867505 | 0.80 | ABCG2 (1.00) | TGFBR1MAPK14ABCG2PDE5ATP53 | |
| SCHEMBL8093527 | 0.80 | ABCG2 (0.82) | ABCG2PDE5ATP53MAPTPOLB | |
| SCHEMBL8816588 | 0.78 | KDM4E (0.50) | TGFBR1MAPK14POLBGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966184-B1 | PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-08-25 | — | — | EP | claimed |
| US-20090306102-A1 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | NEUROSEARCH A/S (DK) | 2009-12-10 | — | — | US | claimed |
| EP-1966184-A2 | PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071632-A2 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | NEUROSEARCH A/S (DK) | 2007-06-28 | — | — | WO | claimed |
| EP-1966184-B1 | PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH AS (DK) | 2010-08-25 | — | — | EP | disclosed |
| US-20090306102-A1 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | NEUROSEARCH A/S (DK) | 2009-12-10 | — | — | US | disclosed |
| EP-1966184-A2 | PYRIDINYL-QUINAZOLINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071632-A2 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | NEUROSEARCH A/S (DK) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306102-A1 | 2-PYRIDIN-2-YL-QUINAZOLINE DERIVATIVES AS POTASSIUM CHANNEL MODULATING AGENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | KCNJ2, KCNQ1, KCNK2 | TGFBR1 3807/4885MAPK14 1505/4885ABCG2 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.